Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology.

Yadav V, Bever C Jr, Bowen J, Bowling A, Weinstock-Guttman B, Cameron M, Bourdette D, Gronseth GS, Narayanaswami P.

Neurology. 2014 Mar 25;82(12):1083-92. doi: 10.1212/WNL.0000000000000250.

2.

Complementary and alternative medical therapies in multiple sclerosis--the American Academy of Neurology guidelines: a commentary.

Yadav V, Narayanaswami P.

Clin Ther. 2014 Dec 1;36(12):1972-8. doi: 10.1016/j.clinthera.2014.10.011. Epub 2014 Nov 15. Review.

PMID:
25467189
3.

Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Wright S, Yadav V, Bever C Jr, Bowen J, Bowling A, Weinstock-Guttman B, Cameron M, Bourdette D, Gronseth GS, Narayanaswami P.

Neurology. 2014 Oct 14;83(16):1484-6. doi: 10.1212/01.wnl.0000455935.13606.91. No abstract available.

PMID:
25313380
4.

Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Koppel BS, Brust JC, Fife T, Bronstein J, Youssof S, Gronseth G, Gloss D.

Neurology. 2014 Apr 29;82(17):1556-63. doi: 10.1212/WNL.0000000000000363. Review.

5.
6.
7.

Summary of evidence-based guideline: periprocedural management of antithrombotic medications in patients with ischemic cerebrovascular disease: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Armstrong MJ, Gronseth G, Anderson DC, Biller J, Cucchiara B, Dafer R, Goldstein LB, Schneck M, Messé SR.

Neurology. 2013 May 28;80(22):2065-9. doi: 10.1212/WNL.0b013e318294b32d. Review.

8.

Cannabinoids and multiple sclerosis.

Pertwee RG.

Pharmacol Ther. 2002 Aug;95(2):165-74. Review.

PMID:
12182963
9.

Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA; American Academy of Neurology.

Neurology. 2013 Jul 30;81(5):463-9. doi: 10.1212/WNL.0b013e31829d86b6. Review. Erratum in: Neurology. 2013 Nov 26;81(22):1968.

PMID:
23897874
10.

Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.

Moreno Torres I, Sanchez AJ, Garcia-Merino A.

Expert Rev Neurother. 2014 Nov;14(11):1243-50. doi: 10.1586/14737175.2014.971758. Review.

PMID:
25331416
11.

Combined cannabinoid therapy via an oromucosal spray.

Perez J.

Drugs Today (Barc). 2006 Aug;42(8):495-503. Review.

PMID:
16969427
12.

Do cannabinoids reduce multiple sclerosis-related spasticity?

Thaera GM, Wellik KE, Carter JL, Demaerschalk BM, Wingerchuk DM.

Neurologist. 2009 Nov;15(6):369-71. doi: 10.1097/NRL.0b013e3181bf5572.

PMID:
19901724
13.

Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.

Oreja-Guevara C.

Expert Rev Neurother. 2012 Apr;12(4 Suppl):3-8. doi: 10.1586/ern.12.11. Review.

PMID:
22509985
14.

Advances in the management of multiple sclerosis spasticity: multiple sclerosis spasticity guidelines.

Gold R, Oreja-Guevara C.

Expert Rev Neurother. 2013 Dec;13(12 Suppl):55-9. doi: 10.1586/14737175.2013.865880. Review.

PMID:
24289845
15.

[There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].

Bazinski H, Jensen HB, Stenager E.

Ugeskr Laeger. 2015 May 11;177(20):956-60. Review. Danish.

PMID:
26535431
16.

Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.

Pozzilli C.

Expert Rev Neurother. 2013 Dec;13(12 Suppl):49-54. doi: 10.1586/14737175.2013.865877. Review.

PMID:
24289844
17.

Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Haselkorn JK, Hughes C, Rae-Grant A, Henson LJ, Bever CT, Lo AC, Brown TR, Kraft GH, Getchius T, Gronseth G, Armstrong MJ, Narayanaswami P.

Neurology. 2015 Nov 24;85(21):1896-903. doi: 10.1212/WNL.0000000000002146. Review.

18.

Cannabis; adverse effects from an oromucosal spray.

Scully C.

Br Dent J. 2007 Sep 22;203(6):E12; discussion 336-7. Epub 2007 Aug 17.

PMID:
17703180
19.

Managing the symptoms of multiple sclerosis: a multimodal approach.

Crayton HJ, Rossman HS.

Clin Ther. 2006 Apr;28(4):445-60. Review.

PMID:
16750459

Supplemental Content

Support Center